Abstract
A prospective survey of benzbromarone (Urinorm®) use was conducted to examine the benzbromarone dose and renal function and their relationships with serum uric acid levels with routine drug usage, particularly the rate of achieving of a serum uric acid level ≤ 6.0mg/dL. Of 3,150 patients whose serum uric acid level had been measured before benzbromarone administration and at least once during the six months of administration, 74.1% achieved a serum uric acid level ≤ 6.0mg/dL six months after the administration of benzbromarone.
In the same way, the rate of achieving a serum uric acid level ≤ 6.0mg/dL was examined in 2,938 of 3,150 patients whose serum uric acid level had been over 7.0 mg/dL before drug administration, and the rate was 73.1% at six months.
For 916 patients whose serum uric acid levels had been measured at all stages (before benzbromarone administration, at one to two months, at three to four months, and at five to six months), the proportion who achieved a serum uric acid level ≤ 6.0mg/dL was 65.1% at one to two months, 77.0% at three to four months, and 81.9% at five to six months after the administration of benzbromarone. Of the 916 patients, 845 had a serum uric acid level > 7.0mg/dL before benzbromarone administration, and their rates of achieving a serum uric acid level ≤ 6.0mg/dL were 63.8, 76.0, and 80.8%, respectively.
The rate of achieving a serum uric acid level ≤ 6.0mg/dL increased with elevations in the benzbromarone dose in all baseline eGFR groups. In addition, in patients with a baseline eGFR ≥ 30mL/min/1.73m2, the rate of achieving a serum uric acid level ≤ 6.0mg/dL was almost the same regardless of the eGFR level.
